BY MARKETWIRE
-
Zealand Pharma explores opportunities in weight-loss pill market
Novo Nordisk and Eli Lilly are concentrating on tablet computer variations of GLP-1 medicines. Zealand Pharma is taking a various strategy with amylin.
-
Novo Nordisk to face rising threat from generic competitors
Novo Nordisk’s license on semaglutide is readied to end in March throughout numerous markets.
-
Novo Nordisk CMO on high-dose Wegovy: More patients reach goals
New EU authorization of Wegovy in high-dose kind will certainly bring about higher weight-loss for individuals.
-
Genmab posts strong revenue growth, earnings below analysts’ expectations
Genmab’s complete income raised to USD 3,720 m from USD 3,121 m.
-
Novo Nordisk faces copy competition in India: Dr. Reddy’s set to launch Wegovy imitation
Indian pharmaceutical business intends to release a common variation of Wegovy at a cost that is 60% less than the cost of Novo Nordisk’s weight-loss medicine.
-
Medtronic delivers slightly better than expected financial results
Revenue rose 8.7% to USD 9.02bn, while analysts had forecast USD 8.9bn.
-
RBTX Launches New Online Shopping Experience for Customers | RoboticsTomorrow
RBTX Launches New On-line Taking a scrutinize Abilities for Customers Customers on RBTX.com can now add system to their cart for buy, or construct an complete machine with assured compatibility The RBTX robotics market, a leader in less pricey automation system and solutions, has officially launched new e-commerce efficiency, allowing possibilities to buy high-cease system
-
Lundbeck earnings potential not fully reflected in current share price, bank says
AL Sydbank keeps in mind that Lundbeck’s current pipe progression alleviates the influence of numerous upcoming license expirations.
-
Novo Nordisk sees Chinese company announcing plans for semaglutide nasal spray
Shanghai Shiling Drug’s objective is to have actually an item based upon semaglutide via scientific tests in 2028.
-
AstraZeneca takes important step towards market with weight-loss tablet
AstraZeneca is expected to enter its oral weight-loss candidate elecoglipron into phase 3 trials later this year.
